Dr. Reddy’s Laboratories Ltd. has announced that it has launched Hervycta® (trastuzumab), a biosimilar of Roche’s Herceptin®, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Dr. Reddy’s Hervycta® is available in strengths of 150mg and 440mg multiple dose vials.
Commenting on the launch, MV Ramana, CEO-Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories, said, “We strive every day to do what matters most for patients. Hervycta® is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space.”
Dr. Raymond De Vré, Senior Vice President and Head, Biologics, Dr. Reddy’s Laboratories, added, “The launch of Hervycta® will immensely benefit women in India who are suffering from HER2-positive breast cancer and are in need of access to high quality, affordable and innovative medicines.”
Herceptin® (marketed as Herclon™ in India) and its biosimilars had India sales of approximately INR 290 Crore MAT for the most recent twelve months ending in December 2017, according to Ipsos*.
Dr. Reddy’s currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.
About Biosimilars Biosimilarity means:
That the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and,
There are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product.